Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cessation of enzyme replacement therapy in Gaucher disease.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Jan 2000

Grinzaid Karen A, Geller Eleanor, Hanna Soheil L, Elsas Louis J

Abstract excerpt

PURPOSE: Enzyme replacement therapy (ERT) is a promising therapeutic intervention for lysosomal storage diseases. Posttranslationally engineered human beta-glucocerebrosidase (Ceredase/Cerezyme) is commercially available and is the standard ERT for Type I Gaucher disease. Cessation of therapy is sometimes necessary for personal or financial reasons, but the consequences of discontinuation are unknown. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gaucher Disease

Share to Genotype

Share to Glucosylceramidase

Share to Recombinant Proteins

Share to Treatment Outcome

Source

Identifiers

PMID: 12509713
DOI: 10.1097/00125817-200211000-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cessation of enzyme replacement therapy in Gaucher disease.PMID 12509713Read ↗

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentSemantic proximity Read ↗

Enzyme therapy for Gaucher disease: the first 5 yearsSemantic proximity Read ↗

Therapeutic goals in Gaucher disease.Semantic proximity Read ↗

Enzyme replacement therapy for Gaucher diseaseSemantic proximity Read ↗

Lessons learned from the development of enzyme therapy for Gaucher disease.Semantic proximity Read ↗

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher diseaseSemantic proximity Read ↗

Emerging Strategies for the Treatment of Hereditary Metabolic Storage DisordersSemantic proximity Read ↗

The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.Semantic proximity Read ↗

Enzyme replacement therapy for Gaucher disease in Australia.Semantic proximity Read ↗

Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial.Semantic proximity Read ↗

Therapy of adult Gaucher disease.Semantic proximity Read ↗

[Enzyme replacement therapy for Gaucher disease introduced in late adulthood].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.